BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Acetaminophen
,
rs2300478
,
MYC
,
Angiogenesis
,
Inflammatory disorder
,
Liver
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
proteins recombinant
Summary
General Info
Curated Studies
Most Correlated Studies
Th2 cytokine IL-4's role in initiating pulmonary vascular inflammation under hypoxia
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
Macrophages from monocytes of donors treated with FVIII or FVIII-Fc fusion protein
Explore Curated Studies Results
Literature
Most Relevant Literature
The implementation of a design of experiments strategy to increase recombinant protein yields in yea…
Recombinant protein production 6 (Vienna, February 2011).
Optimising yeast as a host for recombinant protein production (review).
Disruption of yeast cells to isolate recombinant proteins.
Human cells: new platform for recombinant therapeutic protein production.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years o…
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ